Aplosyn

Fluocinolone

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aplosyn

Property	Description
Active ingredient	Fluocinolone acetonide
Forms	Cream, Ointment, Topical solution, Otic solution
Pharmacological class	Topical Corticosteroid, Glucocorticoid
General purpose	Management of inflammatory symptoms and itching
Origin	Synthetic, Fluorinated hydrocortisone derivative

What Type of Medicine is Aplosyn? (Definition, Class, and Origin)

Aplosyn is a prescription-only medicinal product primarily containing Fluocinolone acetonide, a substance clinically recognized for its potent anti-inflammatory efficacy. The active compound is chemically classified as a synthetic, fluorinated corticosteroid, belonging to the powerful Glucocorticoid pharmacological class. This structure, which is derived from hydrocortisone, gives it superior ability to mitigate inflammation compared to some non-fluorinated counterparts, positioning it as a potent, yet localized treatment. Its classification as a Topical Corticosteroid restricts its route of administration to application directly onto the skin or the ear canal.

Composition and Available Forms of Fluocinolone Acetonide

The Fluocinolone acetonide active ingredient is delivered in several distinct pharmaceutical preparations, enabling both topical and otic administration. The forms range from standard applications like cream and ointment to specialized liquid preparations such as a topical solution designed for the scalp, or an otic solution (ear drops) for aural use. A key differentiation of the Aplosyn range is the existence of specialized forms, including combination products like Aplosyn Otic, which pairs the corticosteroid with anti-infective agents to address inflammation and secondary concerns simultaneously.

What is the General Purpose of Aplosyn?

The fundamental general purpose of Aplosyn is to manage and control the local symptoms of inflammation and pruritus (itching) characteristic of corticosteroid-responsive conditions, such as inflammatory skin reactions. Its mechanism allows it to exert profound Anti-inflammatory and Antipruritic effects, which directly lead to the swift reduction of swelling, redness, and severe discomfort at the application site. This type of corticosteroid is clinically appropriate for use on sensitive areas, supporting its application for conditions requiring focused, potent inflammatory control.

What side effects are possible with Aplosyn?

Possible side effects and safety information

The safety profile of Aplosyn, which contains the potent topical corticosteroid Fluocinolone acetonide, is officially documented based on potential effects at the application site and the risk of systemic absorption.

Local and System-Organ Class Adverse Reactions

Most documented side effects are local, classified under Skin and Subcutaneous Tissue Disorders. These reactions include burning, itching, irritation, dryness, folliculitis, acneiform eruptions, and hypopigmentation. Certain local effects, such as skin atrophy and striae, are associated with prolonged use and are officially noted as potentially irreversible. Systemic effects are classified under Endocrine System Disorders due to the potential for absorption, including Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome.

Frequency and Serious Adverse Reactions

Adverse reactions are reported according to incidence rates derived from clinical trials, such as the 5% incidence of effects like rhinorrhea and fever (pyrexia) in certain formulations. The most serious documented risks relate to systemic absorption. These include HPA axis suppression, which can lead to adrenal insufficiency, and the rare but serious effect of intracranial hypertension, which has been reported in pediatric patients.

Population-Specific Safety Considerations

Pediatric patients are officially noted to demonstrate greater susceptibility to systemic toxicity due to a larger skin surface area to body weight ratio. Specific effects detailed for children include linear growth retardation and delayed weight gain. Furthermore, certain formulations are officially contraindicated in individuals with known sensitivity to peanut-derived materials due to the presence of refined peanut oil NF as an excipient. The risk of adverse reactions is augmented by prolonged use and the use of occlusive dressings.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with topical Fluocinolone acetonide (Aplosyn) is primarily documented as the risk of systemic toxicity resulting from excessive percutaneous absorption. This risk increases with prolonged use, application over large body surface areas, or the use of occlusive dressings. The key physiological manifestation of this systemic exposure is Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, a condition also associated with clinical features resembling Cushing’s syndrome and metabolic changes such as hyperglycemia and glucosuria.

In cases of acute, accidental ingestion (swallowing) of the topical product, regulatory guidance dictates that the user must immediately contact a Poison Control Center or local Emergency Services. A severe potential outcome of established systemic toxicity is the development of Glucocorticosteroid Insufficiency upon abrupt cessation, which requires specific supportive management.

To evaluate systemic toxicity, official procedures require periodic monitoring using tests such as the ACTH Stimulation test or the Urinary Free Cortisol test. If suppression is confirmed, management involves attempting the withdrawal or reduction of the drug. Additionally, pediatric patients are identified as a population more susceptible to systemic toxicity due to a higher skin surface-to-body mass ratio, and chronic exposure may interfere with their growth and development.

Therapeutic Uses of Aplosyn

What Aplosyn Treats: Main Uses and Benefits

Aplosyn is a prescription medication used for topical symptomatic management in situations involving certain distressing symptoms. It is commonly used to help with symptoms related to inflammatory or irritative states, such as itching, redness, swelling, and discomfort. This medication is primarily relevant for managing symptoms associated with conditions involving episodic or fluctuating manifestations, such as psoriasis, eczema (atopic dermatitis), and certain types of dermatitis that produce significant symptomatic burden.

Symptom Relief and Comfort

Aplosyn is considered relevant for managing symptom clusters that may become intense or disruptive, specifically targeting severe and persistent itching and pronounced signs of skin inflammation. It is often applied during phases when symptoms become more noticeable or escalate into a flare-up. The goal is to help address symptoms that interfere with daily functioning. This provides support that helps ease the overall symptom burden and may assist with maintaining a sense of stability during symptomatic phases.

Quick Fact: Relief for Intense Itching

Aplosyn is applied in scenarios where short-term symptomatic assistance is required to manage challenging manifestations on the skin and scalp, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

NIH MedlinePlus overview of a key ingredient

Eligibility and Restrictions for Use

Aplosyn's official eligibility is governed by specific regulatory criteria that define populations for whom use is prohibited, restricted, or where data is insufficient.

Status	Population or Condition
Contraindicated	History of hypersensitivity to the drug or any component, or a peanut allergy for certain formulations containing refined peanut oil. Use is also prohibited in the presence of untreated primary skin infections (bacterial, viral, fungal), rosacea, or napkin eruptions (diaper rash).

The medicine is not established for use in infants younger than 3 months of age. While approved for pediatric patients aged 3 months and older for certain conditions, its use is not recommended in the diaper area, on the face, or on the groin.

Use is restricted during pregnancy, where official documents advise against large amounts or prolonged use, and in nursing mothers, where application to the breasts is prohibited. Caution is also mandatory for patients with pre-existing conditions like Cushing's syndrome or diabetes due to the risk of systemic absorption worsening these endocrine disorders. Furthermore, safety and effectiveness data in older adults (geriatric patients) are officially lacking.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Aplosyn (Fluocinolone acetonide) is primarily determined by its potential for systemic absorption, which can lead to class-specific interactions, rather than specific drug-drug metabolic effects.

Documented Interaction Patterns

Interaction Type	Official Regulatory Statement
Pharmacodynamic Interaction	Co-administration with other corticosteroid-containing products may result in an Additive Glucocorticoid Effect, increasing the potential for systemic exposure and related toxicity.
Exposure-Modifying Factors	Application to large surface areas or use under occlusive dressings increases percutaneous absorption. This increase in systemic exposure carries the formal risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and Cushing’s syndrome manifestations.

Population and Substance Restrictions

Due to a higher skin surface area to body mass ratio, pediatric patients are officially documented as having a greater susceptibility to systemic exposure-related interactions, including HPA axis suppression. The regulatory labeling also contains a product-substance restriction for formulations containing Refined Peanut Oil, which should be avoided by individuals with known peanut hypersensitivity.

No mandatory timing-based separation rules or specific metabolic (CYP-mediated) drug-drug interactions are documented in the official prescribing information for the topical application of Fluocinolone acetonide.

Mechanism of Action

Modulation of Gene Transcription via Glucocorticoid Receptors

Aplosyn's primary mechanistic domain involves its high affinity for intracellular glucocorticoid receptors. Upon binding, the drug-receptor complex translocates into the cell nucleus, where it binds to specific DNA sequences (glucocorticoid response elements). This process modifies the transcription of target genes, leading to the synthesis of certain regulatory proteins, ultimately modulating the expression of target proteins.

Decrease in Inflammatory Signaling Pathways

The drug engages a mechanism that decreases the production of pro-inflammatory mediators. Specifically, it induces proteins like annexin A1 (lipocortin), which inhibits the enzyme phospholipase A2. By modifying this early molecular step, Aplosyn reduces the availability of arachidonic acid, the precursor for inflammatory substances like prostaglandins and leukotrienes. This cascade modification results in the containment of excessive mediator activity, contributing to the attenuation of pathway activity.

Modification of Vascular and Cellular Permeability

Aplosyn exerts its action by inducing vasoconstriction, which in turn reduces vascular permeability. This effect, coupled with a suppression of membrane permeability, decreases the leakage of fluids and the migration of immune cells into the affected tissues. These adjustments contribute to the modification of pathway kinetics and result in physiological adjustments mediated by the drug's interaction with the inflammatory response.

Dosage and Administration Information

Aplosyn (Fluocinolone acetonide) is a medication strictly intended for localized administration, utilized via two official routes: topical (dermal) for the skin and scalp, and otic (aural) for the external ear canal. The drug is supplied in various strengths, including 0.025% cream and 0.01% solutions.

The standard topical dosing regimen involves applying a thin film of the product to the affected area. The general frequency ranges from two to four times daily for lower-potency forms. Use is strictly time-limited, with treatment courses typically not exceeding two consecutive weeks for most indications. Furthermore, certain high-potency topical forms have a weekly quantity restriction, where application generally should not exceed 60 grams.

For otic use, the standard dose is 5 drops instilled into the external ear canal twice daily. Administration technique is formalized in official instructions, which advise warming the single-dose vial in the hands for one to two minutes prior to instillation to facilitate proper use. When applying solutions to hairy areas, the hair must be parted to ensure the medication contacts the affected lesion.

Official administration rules define use by age group: otic and 0.01% topical oil forms are approved for children 2 years of age and older, while certain higher-potency creams are restricted to use in those 12 years of age and older. Once the condition is controlled, the official protocol instructs that therapy should be discontinued, or the frequency reduced to the minimum level required to maintain control.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aplosyn

Fluocinolone Acetonide, the active ingredient in Aplosyn, has was evaluated in research exploring symptoms related to certain inflammatory skin conditions. The evidence available to regulators primarily comes from formal clinical research, including randomized controlled trials (RCTs). These studies help show what has been observed so far regarding how symptoms evolved in the observed populations during periods of increased symptom activity.

Evidence for Use in Psoriasis (Scalp and Skin)

Research exploring Fluocinolone Acetonide for psoriasis was studied for conditions involving periods of heightened symptoms. Studies involved short-term RCTs that included adults and adolescents with mild to moderate plaque psoriasis. These trials were used in research exploring how symptoms change over time by measuring standardized outcomes, such as the Psoriasis Area and Severity Index (PASI) and the Investigator's Global Assessment (IGA).

Studies report findings describe patterns observed in the studies over the study period, which was typically short-term (around two to four weeks). Findings describe patterns related to changes in clinical signs, such as redness, scaling, and thickness. The evidence contributes to the broader evidence landscape when the medication was observed in controlled settings against a vehicle.

Research Gaps and Areas of Uncertainty

The overall research landscape has several limitations that highlight what is still uncertain about Aplosyn. The follow-up durations were limited in many pivotal trials, meaning there is limited information for long-term outcomes and recurrence patterns after the initial treatment phase is complete. The evidence for this indication is generally reliant on small, focused, short-term trial populations.

Dedicated data for other special groups, such as older adults or those with specific comorbidities, data for certain groups remain insufficient, meaning dedicated subgroup findings are uncertain. Evidence highlights what is known — and what is still uncertain regarding the broader application of this compound.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Aplosyn (FAQ)

Q: Is Aplosyn used for other conditions besides the main one listed?

A: Official regulatory documents indicate that Aplosyn is used for relief of inflammatory and pruritic (itchy) symptoms of corticosteroid-responsive dermatoses. This classification covers various skin conditions that respond to this type of medication, which are considered the intended uses.

Q: If I stop taking Aplosyn, will my symptoms return immediately?

A: Aplosyn is typically intended for short-term use, and therapy should be discontinued once the condition is under control. Information regarding long-term recurrence patterns after the treatment course is complete remains limited in the research landscape, indicating uncertainty about how quickly symptoms may return. The recovery of HPA axis function (a systemic effect) upon stopping the medication is generally prompt.

Q: Is Aplosyn known to cause weight gain or weight loss?

A: Weight changes are described as possible manifestations of systemic absorption, which is a risk with this medication. Specifically, these risks include Cushing's syndrome, which may be associated with weight gain in the upper back or belly, and adrenal insufficiency, which can be associated with weight loss.

Q: Why do some people say Aplosyn did not work for them?

A: Clinical studies describe the patterns and outcomes observed in the specific populations tested. However, research evidence notes limitations, indicating uncertainty regarding broader application and individual outcomes. The regulatory documents avoid making claims of guaranteed effectiveness.

Q: What is the risk of dependence or withdrawal with Aplosyn?

A: Aplosyn is not classified as a controlled substance by regulatory bodies, and therefore the risk of dependence is not documented in that context. However, potential systemic effects like adrenal insufficiency can occur during treatment or upon withdrawal of the topical corticosteroid. The recovery of HPA axis (hormone) function is generally prompt after stopping treatment.

Q: Are headaches a common side effect of Aplosyn?

A: The safety information documents side effects related to local skin application and potential systemic absorption. While headache has been reported as an adverse reaction, its frequency is less common or unknown compared to local irritation. Headaches can also be a symptom of a rare but serious effect called intracranial hypertension that has been reported in pediatric patients.

Q: What is the general timeline for seeing the full benefit of Aplosyn?

A: The official clinical trials often observe symptom changes over short-term periods, typically around two to four weeks. Information regarding the full benefit for long-term use and recurrence patterns after this initial phase is subject to research gaps and uncertainty in the evidence.

Q: What happens if I forget to take a dose of Aplosyn?

A: According to general drug information, if a dose is missed, it should be applied as soon as it is remembered, unless it is nearly time for the next scheduled dose. Official protocol states that a double dose should not be applied to make up for a missed dose.

Q: Can Aplosyn affect my mood or energy levels?

A: The risks associated with systemic absorption of Aplosyn include Cushing's syndrome and adrenal insufficiency. These conditions have been associated with symptoms such as unusual tiredness, weakness, depression, anxiety, or irritable mood changes.

Q: Is Aplosyn used with caution for people with kidney problems?

A: Corticosteroids that are absorbed systemically are metabolized in the liver and excreted by the kidneys. Official regulatory documents do not list kidney impairment as a specific contraindication or caution for the topical form.

Q: Is there a generic version of Aplosyn available?

A: Yes, the active ingredient in Aplosyn, Fluocinolone acetonide, is available in FDA-approved generic versions of various topical oil and cream formulations.

Q: What should I do if a mild side effect, like nausea, occurs with Aplosyn?

A: Mild side effects are generally those that may go away on their own within a few days or weeks. Official guidance describes that if any symptoms are severe, persistent, or do not go away, it is necessary to contact a healthcare professional.

Q: How does Aplosyn get eliminated from the body?

A: The drug is intended for localized application. Any portion that is absorbed through the skin is handled like systemically administered corticosteroids. It is metabolized primarily in the liver and then subsequently excreted by the kidneys.

Q: Can Aplosyn affect the results of a blood test?

A: Yes. Because of the risk of the medication being absorbed systemically, it may affect blood tests used to evaluate HPA axis suppression. These include the ACTH stimulation test or plasma cortisol levels.

Q: Have there been any major recalls or safety alerts for Aplosyn?

A: Health authority records indicate that Class II recalls for some formulations containing Fluocinolone acetonide have occurred. These recalls were related to manufacturing specifications of the product. Class II designation indicates that use of the product may cause temporary or medically reversible adverse health consequences.

Q: Is Aplosyn a controlled substance?

A: Aplosyn is a prescription-only medication but is not classified as a controlled substance. It is not listed under the Drug Enforcement Administration ( DEA) schedule.

Q: Does alcohol interact with Aplosyn?

A: Specific metabolic drug-drug interactions involving consumed alcohol are not explicitly documented in the official product information. However, it is noted that some formulations of the drug list isopropyl alcohol as a non-active ingredient (excipient).

Q: Do I need regular checkups or tests while on Aplosyn?

A: Periodic evaluation for HPA axis (hormone) suppression may be required if the drug is used under certain conditions. This is particularly relevant for patients using large doses, applying to large surface areas, or using occlusive (airtight) dressings. Tests may include urinary free cortisol and ACTH stimulation tests.

Q: Can I use Aplosyn if I have liver disease?

A: Liver failure is identified in regulatory documents as a condition that may increase the potential for systemic absorption of the drug. Increased absorption elevates the risk of systemic effects like HPA axis suppression.

How should Aplosyn be stored and disposed of?

How to Store and Dispose of Aplosyn

Aplosyn (Fluocinolone Acetonide) must be stored and handled according to specific regulatory requirements to ensure its stability.

Storage Requirements

Temperature: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept from freezing and excessive heat.
Container: Keep the medication in its original container, tightly closed, and protect it from light and excess moisture; do not store in the bathroom.
Child Safety: Containers must be kept out of the sight and reach of children, and the safety cap must be locked at all times.

Disposal Instructions

Expired or unused Aplosyn should not be discarded in the household trash or flushed down a drain. Individuals must consult a healthcare professional or pharmacist for guidance on disposal. The medication should be taken to an authorized drug take-back program if one is available in the area.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Philippines

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z